Bristol-Myers Squibb

In December 2009, Tranzyme entered into a strategic collaboration with BMS to discover, develop and commercialize novel small molecule macrocyclic compounds using Tranzyme's MATCH™ technology platform. In January 2013, Tranzyme announced the successful completion of the collaboration and that as a result of the joint research efforts, Tranzyme had transferred compounds to Bristol-Myers Squibb for further development across multiple drug targets. As part of this agreement, Tranzyme retained the option to further pursue select collaboration targets for internal development.

Tranzyme is pursuing additional partnership discussions for, TZP-201, TZP-301 and MATCH™, its chemistry-based drug discovery technology. To discuss these opportunities, please contact:

Dave Moore 
Chief Business Officer
dmoore@tranzyme.com
Phone: (919) 328-1122